<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Multiple sclerosis: natilizumab; Natalizumab" /><meta name="IX" content="Multiple sclerosis: natilizumab; Natalizumab" /><title>Natalizumab: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5720-natalizumab.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5720-natalizumab.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5720-natalizumab.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="PHP5665-other-immunomodulating-drugs.htm">8.2.4 Other immunomodulating drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5718-mifamurtide.htm" title="Previous: MIFAMURTIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5724-natalizumab.htm" title="Next: NATALIZUMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304030.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Biologic Response Modifiers 92:20</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20178-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Natalizumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: N &gt; Interactions of Natalizumab</p></div></li></ul><ul><li><h3>British National Formulary (16)</h3></li><li><a href="PHP5150-caverject.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Caverject®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 7 Obstetrics, gynaecology, and urinary-tract disorders &gt; 7.4 Drugs for genito-urinary disorders &gt; 7.4.5 Drugs for erectile dysfunction &gt; Alprostadil &gt; ALPROSTADIL &gt; Intracavernosal injection</p></div></li><li><a href="PHP5151-viridal-duo.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Viridal® Duo</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 7 Obstetrics, gynaecology, and urinary-tract disorders &gt; 7.4 Drugs for genito-urinary disorders &gt; 7.4.5 Drugs for erectile dysfunction &gt; Alprostadil &gt; ALPROSTADIL &gt; Intracavernosal injection</p></div></li><li><a href="PHP5153-muse.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MUSE®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 7 Obstetrics, gynaecology, and urinary-tract disorders &gt; 7.4 Drugs for genito-urinary disorders &gt; 7.4.5 Drugs for erectile dysfunction &gt; Alprostadil &gt; ALPROSTADIL &gt; Urethral application</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22multiple+sclerosis%22%22natalizumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (16)</a></li></ul><ul><li><h3>Dietary Supplements (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c35.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fish oils</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; F</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c42.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ginkgo biloba</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; G</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c98.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Vitamin B12</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; V</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22multiple+sclerosis%22%22natalizumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/n03-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; N</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/11420-l.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interferon Beta</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antivirals &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/18390-s.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Multiple Sclerosis Vaccines</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Vaccines Immunoglobulins and Antisera &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20178-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/06426.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; N &gt; NA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-N14.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; N</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D2248.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Natalizumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; N</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Natalizumab</h1><?highlighter on?><div id="pC" class="jN"> <p id="PHP5721"><strong>Natalizumab</strong> is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination. It is licensed for use in patients with highly active <em>relapsing-remitting multiple sclerosis</em> despite treatment with interferon beta or those with rapidly evolving severe relapsing-remitting multiple sclerosis. Treatment with natalizumab should be initiated and supervised by a specialist.</p> <p>Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML). The risk of developing PML increases with previous immunosuppressant therapy and also after 2 years of therapy; the risk beyond 4 years treatment is not known. A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab, and annually thereafter. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.</p> <p>Infusion-related side-effects include nausea, vomiting, flushing, headache, dizziness, fatigue, rigors, pyrexia, arthralgia, urticaria, and pruritus. Patients should be observed for hypersensitivity reactions, including anaphylaxis, during the infusion and for 1 hour after completion of the infusion. Natalizumab should be discontinued permanently if hypersensitivity reaction occurs.</p> <p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2007) that natalizumab is accepted for restricted use as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.</p> <div id="PHP5723" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007)</h3><p>Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5724-natalizumab"><a href="PHP5724-natalizumab.htm" title="NATALIZUMAB">NATALIZUMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5718-mifamurtide.htm">Previous: MIFAMURTIDE</a> | <a class="top" href="PHP5720-natalizumab.htm#">Top</a> | <a accesskey="]" href="PHP5724-natalizumab.htm">Next: NATALIZUMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>